Cargando…

18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma

SIMPLE SUMMARY: Retroperitoneal sarcomas are difficult malignancies to treat because complete surgical resection is the only effective treatment option, but it is difficult to secure sufficient surgical margins. It is essential for developing a treatment strategy to assess tumor aggressiveness and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakamatsu, Toru, Imura, Yoshinori, Tamiya, Hironari, Yagi, Toshinari, Yasuda, Naohiro, Nakai, Sho, Nakai, Takaaki, Outani, Hidetatsu, Hamada, Kenichiro, Kakunaga, Shigeki, Araki, Nobuhito, Ueda, Takafumi, Takenaka, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471941/
https://www.ncbi.nlm.nih.gov/pubmed/34572838
http://dx.doi.org/10.3390/cancers13184611
_version_ 1784574596994826240
author Wakamatsu, Toru
Imura, Yoshinori
Tamiya, Hironari
Yagi, Toshinari
Yasuda, Naohiro
Nakai, Sho
Nakai, Takaaki
Outani, Hidetatsu
Hamada, Kenichiro
Kakunaga, Shigeki
Araki, Nobuhito
Ueda, Takafumi
Takenaka, Satoshi
author_facet Wakamatsu, Toru
Imura, Yoshinori
Tamiya, Hironari
Yagi, Toshinari
Yasuda, Naohiro
Nakai, Sho
Nakai, Takaaki
Outani, Hidetatsu
Hamada, Kenichiro
Kakunaga, Shigeki
Araki, Nobuhito
Ueda, Takafumi
Takenaka, Satoshi
author_sort Wakamatsu, Toru
collection PubMed
description SIMPLE SUMMARY: Retroperitoneal sarcomas are difficult malignancies to treat because complete surgical resection is the only effective treatment option, but it is difficult to secure sufficient surgical margins. It is essential for developing a treatment strategy to assess tumor aggressiveness and predict prognosis for patients. However, the aggressiveness of retroperitoneal sarcomas before treatment cannot be fully evaluated. In patients with resectable soft tissue sarcomas or several carcinomas, SUV evaluated with FDG-PET has been reported to be a valuable prognostic parameter. However, the correlation between SUVmax on FDG-PET and the prognosis of several histological subtypes in retroperitoneal sarcoma, including dedifferentiated liposarcoma, well-differentiated liposarcoma, and leiomyosarcoma, remains uncertain. This study revealed that SUVmax calculated with FDG-PET was useful as a prognostic factor in retroperitoneal sarcoma, especially in dedifferentiated liposarcoma and Grade2 retroperitoneal sarcoma. ABSTRACT: Background: Retroperitoneal sarcomas are rare neoplasms that occur in the retroperitoneum. Complete surgical resection is the only effective treatment option. The prediction of prognosis by histological diagnosis has not yet been established. The purpose of this study was to identify the usefulness of [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging for validating the prognosis of retroperitoneal sarcoma (RPS) established by histological diagnosis. Methods: We retrospectively reviewed 201 patients with RPS treated at the Osaka International Cancer Institute between 2010 and 2021. We extracted the clinical data, including standardized uptake values (SUVs), evaluated with FDG-PET, and statistically analyzed the data. Results: The median age of patients was 64 years (range, 31–85 years). A total of 101 (50.2%) patients were men, and 100 (49.8%) were women. Surgical resection was performed in 155 (77.1%) patients. On histological analysis, 75 (37.3%), 52 (25.9%), and 29 (14.4%) patients were diagnosed with dedifferentiated liposarcoma, well-differentiated liposarcoma, and leiomyosarcoma, respectively. The median survival time for patients with high maximum SUV (SUVmax) (≥4) or low SUVmax (<4) was 275.8 months and 79.5 months, respectively. Furthermore, among the patients with dedifferentiated liposarcoma, the overall survival rate for patients with high SUVmax (≥4) was significantly lower than that of those with low SUVmax (<4). Conclusions: The present study demonstrated that SUVmax calculated with FDG-PET was useful as a prognostic factor in RPS, especially in dedifferentiated liposarcoma and Grade2 RPS. To devise a treatment strategy for RPS, SUVmax during FDG-PET scan may be considered for clinical assessment.
format Online
Article
Text
id pubmed-8471941
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84719412021-09-28 18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma Wakamatsu, Toru Imura, Yoshinori Tamiya, Hironari Yagi, Toshinari Yasuda, Naohiro Nakai, Sho Nakai, Takaaki Outani, Hidetatsu Hamada, Kenichiro Kakunaga, Shigeki Araki, Nobuhito Ueda, Takafumi Takenaka, Satoshi Cancers (Basel) Article SIMPLE SUMMARY: Retroperitoneal sarcomas are difficult malignancies to treat because complete surgical resection is the only effective treatment option, but it is difficult to secure sufficient surgical margins. It is essential for developing a treatment strategy to assess tumor aggressiveness and predict prognosis for patients. However, the aggressiveness of retroperitoneal sarcomas before treatment cannot be fully evaluated. In patients with resectable soft tissue sarcomas or several carcinomas, SUV evaluated with FDG-PET has been reported to be a valuable prognostic parameter. However, the correlation between SUVmax on FDG-PET and the prognosis of several histological subtypes in retroperitoneal sarcoma, including dedifferentiated liposarcoma, well-differentiated liposarcoma, and leiomyosarcoma, remains uncertain. This study revealed that SUVmax calculated with FDG-PET was useful as a prognostic factor in retroperitoneal sarcoma, especially in dedifferentiated liposarcoma and Grade2 retroperitoneal sarcoma. ABSTRACT: Background: Retroperitoneal sarcomas are rare neoplasms that occur in the retroperitoneum. Complete surgical resection is the only effective treatment option. The prediction of prognosis by histological diagnosis has not yet been established. The purpose of this study was to identify the usefulness of [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging for validating the prognosis of retroperitoneal sarcoma (RPS) established by histological diagnosis. Methods: We retrospectively reviewed 201 patients with RPS treated at the Osaka International Cancer Institute between 2010 and 2021. We extracted the clinical data, including standardized uptake values (SUVs), evaluated with FDG-PET, and statistically analyzed the data. Results: The median age of patients was 64 years (range, 31–85 years). A total of 101 (50.2%) patients were men, and 100 (49.8%) were women. Surgical resection was performed in 155 (77.1%) patients. On histological analysis, 75 (37.3%), 52 (25.9%), and 29 (14.4%) patients were diagnosed with dedifferentiated liposarcoma, well-differentiated liposarcoma, and leiomyosarcoma, respectively. The median survival time for patients with high maximum SUV (SUVmax) (≥4) or low SUVmax (<4) was 275.8 months and 79.5 months, respectively. Furthermore, among the patients with dedifferentiated liposarcoma, the overall survival rate for patients with high SUVmax (≥4) was significantly lower than that of those with low SUVmax (<4). Conclusions: The present study demonstrated that SUVmax calculated with FDG-PET was useful as a prognostic factor in RPS, especially in dedifferentiated liposarcoma and Grade2 RPS. To devise a treatment strategy for RPS, SUVmax during FDG-PET scan may be considered for clinical assessment. MDPI 2021-09-14 /pmc/articles/PMC8471941/ /pubmed/34572838 http://dx.doi.org/10.3390/cancers13184611 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wakamatsu, Toru
Imura, Yoshinori
Tamiya, Hironari
Yagi, Toshinari
Yasuda, Naohiro
Nakai, Sho
Nakai, Takaaki
Outani, Hidetatsu
Hamada, Kenichiro
Kakunaga, Shigeki
Araki, Nobuhito
Ueda, Takafumi
Takenaka, Satoshi
18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma
title 18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma
title_full 18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma
title_fullStr 18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma
title_full_unstemmed 18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma
title_short 18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma
title_sort 18f-fluorodeoxyglucose positron emission tomography is useful in the evaluation of prognosis in retroperitoneal sarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471941/
https://www.ncbi.nlm.nih.gov/pubmed/34572838
http://dx.doi.org/10.3390/cancers13184611
work_keys_str_mv AT wakamatsutoru 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT imurayoshinori 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT tamiyahironari 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT yagitoshinari 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT yasudanaohiro 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT nakaisho 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT nakaitakaaki 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT outanihidetatsu 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT hamadakenichiro 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT kakunagashigeki 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT arakinobuhito 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT uedatakafumi 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma
AT takenakasatoshi 18ffluorodeoxyglucosepositronemissiontomographyisusefulintheevaluationofprognosisinretroperitonealsarcoma